BioAge Labs (BIOA) Stock Analysis & AI Equity Report
BioAge Labs (BIOA) overview
BioAge Labs (BIOA) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 9.0m and operating profit of USD -92.8m; the year-end share price was 13.23 USD and market capitalisation was USD 495m. BioAge Labs is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get BioAge Labs's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About BioAge Labs
BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic candidates for metabolic diseases based on research into human aging biology. Its programs include an oral small-molecule inhibitor being developed for cardiometabolic disease and ophthalmology, and apelin receptor agonists for obesity. The company also advances platform-derived discovery programs through collaborations with pharmaceutical companies.
Generate the BioAge Labs report
BioAge Labs is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for BioAge Labs and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on BioAge Labs
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.